Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge
- PMID: 12819074
- PMCID: PMC161983
- DOI: 10.1128/IAI.71.7.3894-3900.2003
Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge
Abstract
Toll-like receptor 2 (TLR2) is a transmembrane signal transducer for tripalmitoyl-S-glyceryl-cysteine (Pam(3)Cys)-modified lipoproteins, including OspA from the Lyme disease spirochete Borrelia burgdorferi. The Pam(3)Cys modification provides adjuvant activity for inducing humoral responses, suggesting that TLR2 could function as the adjuvant receptor for the OspA vaccine. The importance of TLR2 in the humoral response to OspA was confirmed, because overall levels of immunoglobulin G (IgG) were reduced in TLR2-deficient mice, when compared with those in wild-type mice. However, the levels of production of IgG1 were similar in both mouse strains, and the levels of induction of protective immunity were comparable. Unlipidated OspA was not immunogenic in wild-type or TLR2-deficient mice, indicating the lipid modification was active in the absence of TLR2. These findings indicate that the Pam(3)Cys modification of bacterial lipoprotein has adjuvant properties independent of TLR2 signaling.
Figures




Similar articles
-
The Lyme disease vaccine takes its toll.Vector Borne Zoonotic Dis. 2002 Winter;2(4):217-22. doi: 10.1089/153036602321653798. Vector Borne Zoonotic Dis. 2002. PMID: 12804162
-
Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice.Nat Med. 2002 Aug;8(8):878-84. doi: 10.1038/nm732. Epub 2002 Jul 1. Nat Med. 2002. PMID: 12091878 Clinical Trial.
-
Toll-like receptor 2 is required for innate, but not acquired, host defense to Borrelia burgdorferi.J Immunol. 2002 Jan 1;168(1):348-55. doi: 10.4049/jimmunol.168.1.348. J Immunol. 2002. PMID: 11751980
-
Vaccination as a modality to prevent Lyme disease. A status report.Infect Dis Clin North Am. 1999 Mar;13(1):135-48, vii. doi: 10.1016/s0891-5520(05)70047-7. Infect Dis Clin North Am. 1999. PMID: 10198796 Review.
-
Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.J Infect Dev Ctries. 2017 Jan 30;11(1):1-9. doi: 10.3855/jidc.7999. J Infect Dev Ctries. 2017. PMID: 28141584 Review.
Cited by
-
Borrelia burgdorferi elicited-IL-10 suppresses the production of inflammatory mediators, phagocytosis, and expression of co-stimulatory receptors by murine macrophages and/or dendritic cells.PLoS One. 2013 Dec 19;8(12):e84980. doi: 10.1371/journal.pone.0084980. eCollection 2013. PLoS One. 2013. PMID: 24367705 Free PMC article.
-
Investigating disease severity in an animal model of concurrent babesiosis and Lyme disease.Int J Parasitol. 2019 Feb;49(2):145-151. doi: 10.1016/j.ijpara.2018.06.006. Epub 2018 Oct 24. Int J Parasitol. 2019. PMID: 30367867 Free PMC article. Review.
-
Toll or toll-free adjuvant path toward the optimal vaccine development.J Clin Immunol. 2007 Jul;27(4):363-71. doi: 10.1007/s10875-007-9087-x. Epub 2007 Mar 17. J Clin Immunol. 2007. PMID: 17370119 Review.
-
Host transcriptome response to Borrelia burgdorferi sensu lato.Ticks Tick Borne Dis. 2021 Mar;12(2):101638. doi: 10.1016/j.ttbdis.2020.101638. Epub 2020 Dec 13. Ticks Tick Borne Dis. 2021. PMID: 33360384 Free PMC article. Review.
-
NERVE: new enhanced reverse vaccinology environment.BMC Biotechnol. 2006 Jul 18;6:35. doi: 10.1186/1472-6750-6-35. BMC Biotechnol. 2006. PMID: 16848907 Free PMC article.
References
-
- Akira, S., K. Takeda, and T. Kaisho. 2001. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2:675-680. - PubMed
-
- Alexopoulou, L., V. Thomas, M. Schnare, Y. Lobet, J. Anguita, R. T. Schoen, R. Medzhitov, E. Fikrig, and R. A. Flavell. 2002. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8:878-884. - PubMed
-
- Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285:736-739. - PubMed
-
- Barthold, S. W., D. S. Beck, G. M. Hansen, G. A. Terwilliger, and K. D. Moody. 1990. Lyme borreliosis in selected strains and ages of laboratory mice. J. Infect. Dis. 162:133-138. - PubMed
-
- Bessler, W. G., B. Suhr, H. J. Buhring, C. P. Muller, K. H. Wiesmuller, G. Becker, and G. Jung. 1985. Specific antibodies elicited by antigen covalently linked to a synthetic adjuvant. Immunobiology 170:239-244. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R29 AI043521/AI/NIAID NIH HHS/United States
- R01 AI024158/AI/NIAID NIH HHS/United States
- AI-43521/AI/NIAID NIH HHS/United States
- 5P30-CA-42014/CA/NCI NIH HHS/United States
- P51 RR000164/RR/NCRR NIH HHS/United States
- R01 AI049976/AI/NIAID NIH HHS/United States
- AI-32223/AI/NIAID NIH HHS/United States
- R01 AI043521/AI/NIAID NIH HHS/United States
- RR00164/RR/NCRR NIH HHS/United States
- AI49976/AI/NIAID NIH HHS/United States
- R56 AI032223/AI/NIAID NIH HHS/United States
- AI-24158/AI/NIAID NIH HHS/United States
- R01 AI032223/AI/NIAID NIH HHS/United States
- P30 CA042014/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous